Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
1
20%
Ph not_applicable
3
60%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 31 (20.0%)
N/A3 (60.0%)

Trials by Status

terminated120%
completed360%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

CGM Plus GEM in Prediabetes

NCT05580978
completednot_applicable

The GEM (Goals for Eating and Moving) Study

NCT03006328
terminatedphase_1

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

NCT03267940
unknownphase_3

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

NCT03006614
completednot_applicable

Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations

NCT02432391

Clinical Trials (5)

Showing 5 of 5 trials
NCT05580978Not Applicable

CGM Plus GEM in Prediabetes

Completed
NCT03006328Not Applicable

The GEM (Goals for Eating and Moving) Study

Completed
NCT03267940Phase 1

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Terminated
NCT03006614Phase 3

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Unknown
NCT02432391Not Applicable

Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5